<p>
<s>the high courts ruling cast a spotlight on this sector but look past health care reforms early winners</s>
</p>

<p>
<s>this column appeared in the september issue of money magazine</s>
</p>

<p>
<s>by paul r la monica</s>
</p>

<p>
<s>after the supreme court upheld the affordable care act the prognosis for health care shares generally improved</s>
<s>some managedcare companies and hospitals were dubbed big winners since reforms survival means that more americans will probably utilize  and have the coverage to pay for  medical services</s>
</p>

<p>
<s>while the ruling clearly lifted a huge uncertainty from this sector its naive to think that chief justice john roberts had the last say on reform</s>
<s>republicans and democrats have been fighting about health care since theodore roosevelt was president says les funtleyder a manager at poliwogg a hedge fund that specializes in health care stocks</s>
</p>

<p>
<s>related hedge funds bet on obamacare</s>
</p>

<p>
<s>so instead of focusing on the immediate beneficiaries  which would after all lose the most if health laws were overhauled again down the road  stick with companies that stand to grow in the long run with or without reform says peter tuz a manager with chase investment counsel</s>
</p>

<p>
<s>fast pharma</s>
</p>

<p>
<s>this list includes medicaldevice makers and some fastgrowing drug stocks</s>
<s>its a simple matter of demographics argues funtleyder</s>
</p>

<p>
<s>as baby boomers age they will need to see their physicians more often</s>
<s>increased doctor visits coupled with broader coverage mean more prescriptions</s>
<s>tuzs fund chase growth owns drugstore giant cvs caremark which controls nearly 20 of the retail prescriptiondrug market</s>
</p>

<p>
<s>other stocks he likes genericdrug maker perrigo which benefits from the surge in storebrand overthecounter sales in this weak economy and the specialtydrug and medicaldevice maker allergan</s>
<s>its flagship product botox is being used for broader applications like migraines and urinary incontinence</s>
</p>

<p>
<s>none of these stocks trade at rockbottom priceearnings ratios</s>
<s>in this slowgrowing sector though dirtcheap stocks often deserve to be</s>
<s>cvs perrigo and allergan by contrast are expected to post annual earnings gains of at least 12 for the next five years</s>
</p>

<p>
<s>investors without borders</s>
</p>

<p>
<s>another place to look for fastgrowing health care companies is overseas</s>
</p>

<p>
<s>the growth in health care is likely to be mostly outside the us as access to medical services improves in the developing world says joe costigan director of equity research at bryn mawr trust</s>
<s>costigans fund owns mindray medical a chinese maker of diagnostic devices whose earnings are rising 15 annually</s>
</p>

<p>
<s>prefer investing in foreign stocks through a mutual or exchangetraded fund</s>
<s>among the top holdings of spdr sp international healthcare sector etfÂ  is novo nordisk</s>
<s>the danish drug giant controls around half of the global market for insulin and its earnings are forecast to grow nearly three times as fast as the pharmaceutical sectors</s>
</p>

